IBRX Stock Analysis: Buy, Sell, or Hold?
IBRX - ImmunityBio, Inc. Common Stock
$7.32
0.10 (1.39%)
▲
5d:
+2.66%
30d:
-5.43%
90d:
-22.13%
BUY
HIGH Confidence
Analysis Updated: Jun 23, 2026 12:00 AM ET
Earnings: Aug 04, 2026
Smart Money Distribution
None View Scanner →
Strength: 9.0/10
Get Alerted When IBRX Hits Your Target Price
Join 10,000+ traders who never miss a move
You're in! Check your email to confirm and set your target price.
100% Free
No spam, ever
Unsubscribe anytime
Interactive Price Chart (1 Month)
Loading chart...
Loading historical data...
Bottom Line:
✅ BUY SIGNAL: IBRX shows strong fundamentals and good volume confirmation. Solid entry point despite fair pricing.
✅ BUY SIGNAL: IBRX shows strong fundamentals and good volume confirmation. Solid entry point despite fair pricing.
In-depth Analysis How we analyze
Valuation Analysis: IBRX is currently trading at $7.32, which is considered fair relative to its 30-day fair value range of $7.02 to $7.75. The stock's valuation (Forward PE: 122.0) is in line with its historical norms (133.1). Remarkably, the market is currently pricing in an annual earnings decline of 2.9% over the next few years. This aligns with recent fundamental challenges.
Technical Outlook: Technically, IBRX is in a downtrend. Immediate support is located at $6.68, while resistance sits at $7.60.
Market Sentiment: IBRX has a strong technical setup (60/100), with favorable trendlines, momentum, and price action for short-term traders. Wall Street analysts see significant upside, with an average price target of $13.00 (+77.6%). Combining these factors, the current setup offers a favorable risk/reward ratio for buyers.
Technical Outlook: Technically, IBRX is in a downtrend. Immediate support is located at $6.68, while resistance sits at $7.60.
Market Sentiment: IBRX has a strong technical setup (60/100), with favorable trendlines, momentum, and price action for short-term traders. Wall Street analysts see significant upside, with an average price target of $13.00 (+77.6%). Combining these factors, the current setup offers a favorable risk/reward ratio for buyers.
Quick Decision Summary
Current Position
FAIR
Historical Trading Range
$7.02 -
$7.75
Company Quality Score
65/100
(BUY)
Volume Confirmation
HIGH
Confidence Score
83.3%
All Signals
- NEUTRAL: Price in fair range
- BULLISH: Strong technical setup (60/100)
- BULLISH: High volume confirmation
- BULLISH: Trading 77.6% below Wall St target ($13.00)
Trading Range Analysis
30-Day Trading Range
$7.02 -
$7.75
Current vs Trading Range
FAIR
Support & Resistance Levels
Support Level
$6.69
Resistance Level
$7.60
Current Trend
Downtrend
Technical data as of
Jun 23, 2026
Fundamental Context
Forward P/E (Next Year Est.)
122.00
Wall Street Target
$13.00
(+77.6%)
Revenue Growth (YoY)
167.6%
Valuation Discount vs History
-2.9% cheaper
PE vs Historical
122.0 vs 133.1
FAIR
Market-Implied Price Targets
If current PE multiple persists
Implied Growth (YoY):
-2.9%
(market-implied from PE analysis)
1-Year Target
$7.11
(-3%)
2-Year Target
$6.90
(-6%)
3-Year Target
$6.70
(-9%)
3-Yr Target (if PE normalizes)
(PE: 122→133)
$7.31
(0%)
💡
Upside Surprise Potential
If earnings stabilize (0% growth), PE could expand from 122.0 to 133.1
Stabilization Target:
$7.99
(+9.1%)
PE Expansion Potential:
+9.1%
Share & Embed Analysis
Last updated: June 23, 2026 11:21 PM ET
Data refreshes hourly during market hours. Next update: 12:21 AM
Data refreshes hourly during market hours. Next update: 12:21 AM
🔥 Top Stocks Breaking Out Now
| Ticker | Score | Recommendation | Change % |
|---|
Technical Signals Check
Is IBRX showing a specific setup today?
Insider Activity (6 Months)
0
Buys
7
Sells
Net
INSIDERS SELLING
Recent Transactions
Barry J Simon
SELL
75000 shares
2026-02-24
Barry J Simon
SELL
165000 shares
2026-02-23
Christobel Selecky
SELL
25000 shares
2026-02-23
Top Rated Biotechnology Stocks
Top-rated stocks in Biotechnology by analyst ratings.
| Stock | Analyst Consensus | Analyst Target | Tradestie Score |
|---|---|---|---|
|
NTLA
Intellia Therapeutics Inc |
STRONG BUY
29 analysts |
$27 | 56 HOLD |
|
ONC
BeiGene, Ltd. |
STRONG BUY
24 analysts |
$412 | 57 HOLD |
|
ARGX
argenx NV ADR |
STRONG BUY
22 analysts |
$1022 | 67 BUY |
|
INSM
Insmed Inc |
STRONG BUY
21 analysts |
$197 | 61 BUY |
|
ACLX
Arcellx Inc |
STRONG BUY
18 analysts |
$113 | 57 HOLD |
Advanced IBRX Option Strategies
Professional options setups generated by AI based on today's IBRX price and gamma walls.
